Hong Kong-led study discovers simeprevir as potent treatment for Covid-19


HONG KONG, May 10 (Xinhua): A Hong Kong-led global study showed that a hepatitis C virus drug simeprevir can strongly suppress the replication of SARS-CoV-2, the virus that causes Covid-19, according to a press release issued by the Chinese University of Hong Kong (CUHK) on Monday.

Since the beginning of 2020, researchers from the CUHK and the University of Hong Kong have collaborated with over 30 scientists from local and overseas laboratories to search for an effective drug molecule for the treatment of Covid-19.

Using a combination of biochemistry, cell biology and computational chemistry techniques, the team discovered simeprevir can simultaneously target two major viral proteins that are critical to viral replication. Simeprevir is by now the only antiviral drug that can target more than one SARS-CoV-2 protein.

Billy Wai Lung Ng, a professor from the CUHK's faculty of medicine, said that simeprevir is an antiviral agent used for the treatment of hepatitis C by inhibiting the activity of viral protease so as to suppress viral replication.

Michael Chi Wai Chan, an associate professor of the School of Public Health from the HKU's faculty of medicine, said the team also evaluated the antiviral effect of simeprevir together with remdesivir.

The results showed that with 3.3 uM of remdesivir and simeprevir, the antiviral effect was increased over 100-fold when compared with remdesivir alone.

David Shu Cheong Hui, an respiratory medicine expert from the CUHK, said that recent research studies suggested that the existing vaccines and drugs may not be able to combat the emerging mutants of the virus effectively.

"Moreover, the recurring coronavirus epidemics in the last two decades suggest that the virus may become a persistent healthcare issue threatening global health. It is therefore essential to enlarge our therapeutic box in preparation for future coronavirus pandemics," Hui said.

The results of the study have been published in a leading international chemistry journal ACS Central Science. Enditem
Article type: metered
User Type: anonymous web
User Status:
Campaign ID: 46
Cxense type: free
User access status: 3
   

Next In Aseanplus News

Delta COVID variant becoming globally dominant, WHO official says
Asean News Headlines as at 9pm on Friday (June 18)
Singapore sees first day rush for Sinovac vaccine; as 16 Covid-19 cases announced on Friday (June 18)
Indonesia reports highest number of daily Covid-19 cases since late January; 12, 990 cases on Friday (June 18)
Three million Chinese jabs heading to Thailand, says PM as Covid-19 cases continues to surge in country
Philippines Covid-19 cases total almost 1.35 million as govt allows more health workers are allowed to go abroad
U.N. chief Guterres appointed for second term
Ho Chih Minh City leads Vietnam's Covid-19 tally on Friday (June 18) with highest daily increase
UN Assembly to vote on resolution condemning Myanmar junta
Switzerland topples Singapore in IMD's world competitiveness ranking; first time in 33 years for the Swiss

Stories You'll Enjoy


Vouchers